Delavirdine description: Difference between revisions
Ahmed Zaghw (talk | contribs) No edit summary |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AZ}} | {{CMG}}; {{AE}} {{AZ}} | ||
==DESCRIPTION== | |||
RESCRIPTOR Tablets contain delavirdine mesylate, a synthetic non-nucleoside reverse transcriptase inhibitor (NNRTI) of the human immunodeficiency virus type 1 (HIV-1). The chemical name of delavirdine mesylate is piperazine, 1-[3-[(1-methyl-ethyl)amino]-2- pyridinyl]-4-[[5-[(methylsulfonyl)amino]-1H-indol-2-yl]carbonyl]-, monomethanesulfonate. Its molecular formula is C22H28N6O3S•CH4O3S, and its molecular weight is 552.68. The structural formula is: | |||
{| | |||
|[[File:Del01.JPG|600px|thumb]] | |||
|} | |||
Delavirdine mesylate is an odorless white-to-tan crystalline powder. The aqueous solubility of delavirdine free base at 23°C is 2,942 mcg/mL at pH 1.0, 295 mcg/mL at pH 2.0, and 0.81 mcg/mL at pH 7.4. | |||
Each RESCRIPTOR Tablet, for oral administration, contains 100 or 200 mg of delavirdine mesylate (henceforth referred to as delavirdine). Inactive ingredients consist of carnauba wax, colloidal silicon dioxide, croscarmellose sodium, lactose, magnesium stearate, and microcrystalline cellulose. In addition, the 100-mg tablet contains Opadry White YS-1-7000-E and the 200-mg tablet contains hypromellose and Opadry White YS-1-18202-A. | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = RESCRIPTOR (DELAVIRDINE MESYLATE) TABLET [VIIV HEALTHCARE COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eb28dcd2-c457-4137-9eec-00062e5a601b | publisher = | date = | accessdate = 1 January 2014 }}</ref> | <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = RESCRIPTOR (DELAVIRDINE MESYLATE) TABLET [VIIV HEALTHCARE COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eb28dcd2-c457-4137-9eec-00062e5a601b | publisher = | date = | accessdate = 1 January 2014 }}</ref> | ||
Revision as of 22:40, 1 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
DESCRIPTION
RESCRIPTOR Tablets contain delavirdine mesylate, a synthetic non-nucleoside reverse transcriptase inhibitor (NNRTI) of the human immunodeficiency virus type 1 (HIV-1). The chemical name of delavirdine mesylate is piperazine, 1-[3-[(1-methyl-ethyl)amino]-2- pyridinyl]-4-[[5-[(methylsulfonyl)amino]-1H-indol-2-yl]carbonyl]-, monomethanesulfonate. Its molecular formula is C22H28N6O3S•CH4O3S, and its molecular weight is 552.68. The structural formula is:
 |
Delavirdine mesylate is an odorless white-to-tan crystalline powder. The aqueous solubility of delavirdine free base at 23°C is 2,942 mcg/mL at pH 1.0, 295 mcg/mL at pH 2.0, and 0.81 mcg/mL at pH 7.4.
Each RESCRIPTOR Tablet, for oral administration, contains 100 or 200 mg of delavirdine mesylate (henceforth referred to as delavirdine). Inactive ingredients consist of carnauba wax, colloidal silicon dioxide, croscarmellose sodium, lactose, magnesium stearate, and microcrystalline cellulose. In addition, the 100-mg tablet contains Opadry White YS-1-7000-E and the 200-mg tablet contains hypromellose and Opadry White YS-1-18202-A. [1]
References
- ↑ "RESCRIPTOR (DELAVIRDINE MESYLATE) TABLET [VIIV HEALTHCARE COMPANY]". Retrieved 1 January 2014.
Adapted from the FDA Package Insert.